Subscribe To

Price Alert Latest News Economic Calendar News

RLAY / Relay Therapeutics Highlights Interim Data From Bile Duct Cancer Trial

Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer) and multiple other solid tumors. The data were shared at the AACR-NCI-EORTC Molecular Targets Conference. Read More

Demo Live Account See Partner Details

Content Topics

Direxion

Daily

Csi

300 China

Bear

1x

Chad

Therapeutics

Highlights

Interim

Cancer

Stock

RLAY

Posted: Oct 8 2021, 12:24

Author Name: Benzinga

RLAY News

By GlobeNewsWire
September 18, 2023

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming

By Zacks Investment Research
August 8, 2023

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compare

By Seeking Alpha
July 28, 2023

Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608

Relay Therapeutics' early clinical data for cancer drug RLY-2608 sparked investor concerns due to lack of robust evidence of efficacy, leading to a 40

By Zacks Investment Research
May 4, 2023

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates

Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.70. This compare

By Zacks Investment Research
April 14, 2023

Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?

Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mi

By Zacks Investment Research
April 6, 2023

Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in Relay Therapeutics, Inc. (RLAY). While the effective

By GlobeNewsWire
March 1, 2023

Relay Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this mo

By Seeking Alpha
January 18, 2023

Relay Therapeutics: Tall Claims, Some Proofs Of Concept, Some Concerns

Relay Therapeutics, Inc. discovers drugs using a novel computational approach. There is some proof of concept data.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.